BRIGHT MINDS BIOSCIENCES INC (DRUG)
CA10919W4056 - Common Stock
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
Bright Minds Biosciences to Present Data at the American Epilepsy Society 2024 Annual Meeting
- Poster presentations on BMB-101 will focus on 5-HT2C functional selectivity and Phase 1 clinical data - NEW YORK, Nov. 21, 2024 (GLOBE NEWSWIRE) --...
Meet the Biotech Stock That Has Generated Nvidia-Like Returns in Less Than a Month
The reason for the stock's rapid ascent is a mystery.
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
Bright Minds Biosciences Closes US$35 Million Non-Brokered Private Placement
VANCOUVER, British Columbia, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”)...
Bright Minds Biosciences and Firefly Neuroscience to Collaborate After the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy for Full Analysis of EEG Data
NEW YORK AND VANCOUVER, British Columbia, Oct. 21, 2024 (GLOBE NEWSWIRE) -- Bright Minds Biosciences Inc. (Bright Minds or the Company) (NASDAQ: DRUG), a...
Bright Minds Biosciences Announces US$35 Million Non-Brokered Private Placement
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN...
Bright Minds Biosciences (NASDAQ: DRUG) Soars 1800% Amid Short Squeeze Alongside PRSO, ILLR and NIVF
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models
Bright Minds Biosciences proprietary compound, BMB-201, 5-HT2C/2A mixed agonist, demonstrated similar efficacy to morphine in preclinical pain models ...
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences announces participation in upcoming scientific conferences and partnering events
Bright Minds Biosciences Inc. (NASDAQ: DRUG) is excited to announce its participation in the upcoming scientific conferences...
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences to Host Investor & Analyst KOL Event on September 25th
Bright Minds Biosciences will host the Key Opinion Leader event with leading experts in epilepsy research and treatment on September 25...
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
/PRNewswire/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and...
Bright Minds Biosciences Initiates the BREAKTHROUGH Study: A Phase 2 Trial of BMB-101 in Absence Epilepsy and Developmental Epileptic Encephalopathy
/CNW/ - Bright Minds Biosciences Inc. (NASDAQ: DRUG), a biotechnology company focused on developing novel therapies for neurological and neuropsychiatric...
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
Bright Minds Biosciences just reported results for the third quarter of 2024.
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q3 2024
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Bright Minds Biosciences (NASDAQ:DRUG) just reported results for the third quar...
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to dive into the biggest pre-market stock movers for Monday morning with all of the latest news affecting shares today!
DRUG Stock Earnings: Bright Minds Biosciences Reported Results for Q2 2024
Bright Minds Biosciences just reported results for the second quarter of 2024.
Psychedelic stocks gain after FDA priority review for MDMA therapy (NYSE:CYBN)
The FDA priority review for an MDMA-linked therapy leads to a surge in shares of psychedelic medicine companies such as Mind Medicine (MNMD). Read more here.